Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE:CLVT) has released a new report titled Extending the Human Lifespan, exploring advancements in anti-aging science and the development of potential drugs. The report highlights a significant rise in the global population aged 65 and older, creating a demand for solutions to enhance both lifespan and quality of life. Key findings include 139 ongoing trials for seven existing drugs that might extend lifespan, raising $1.95 billion for aging-related companies since 2020. However, there are concerns regarding gender disparities in aging research.
Clarivate Plc (NYSE:CLVT) announced the retirement of Jerre Stead as CEO, effective September 1, 2022, after three years of leadership during which the company nearly tripled in size. Jonathan Gear has been appointed as CEO-elect, starting July 11, 2022, with a strong background in technology and data services, previously serving as CFO of IHS Markit. Mr. Stead will transition to Non-Executive Chair of the Board, emphasizing the confidence in Mr. Gear to lead the company forward. Clarivate aims to position itself as a leading provider of innovative solutions.
Clarivate Plc (NYSE: CLVT) announced it will release its second quarter 2022 financial results on August 9, 2022, prior to market opening. The earnings report and financial details will be available on the investor website. A conference call and webcast to discuss the results will occur on the same day at 9:00 AM Eastern Time. Interested parties can join the call via a dedicated phone line or access the live webcast through the company’s investor relations site. A replay will be available for a limited time following the call.
Clarivate Plc (NYSE: CLVT) has been selected for the second consecutive time to provide citation data for the Australian Research Council's Excellence in Research for Australia (ERA) 2023. This initiative aims to evaluate research excellence across Australian universities. Utilizing The Web of Science™, Clarivate will support the ARC in assessing research quality through citation indicators and peer reviews. Clarivate has been involved with ERA since its inception in 2010, continually implementing improvements to enhance research evaluations.
Clarivate Plc (NYSE: CLVT) has released its 2022 Journal Citation Reports (JCR), highlighting ongoing increases in citation impact for journals publishing COVID-19 research. Notably, The Lancet now holds the top Journal Impact Factor of 202.731, surpassing the New England Journal of Medicine, while Nature becomes the first journal to exceed one million citations in a year. The JCR assesses over 21,000 journals with rigorous criteria, emphasizing the profound influence of COVID-19 on academic publishing.
Clarivate Plc (NYSE: CLVT) announced that Jerre Stead and Jonathan Collins will present at investor conferences in June 2022. Key dates include the Stifel 2022 Cross Sector Insight Conference on June 7, 2022, at 9:10 AM ET, and the William Blair’s 42nd Annual Growth Stock Conference on June 9, 2022, at 2:20 PM ET. Live webcasts will be available for both events, with replays accessible afterwards. Clarivate aims to provide solutions that accelerate innovation across various sectors, including Life Sciences and Technology.
Clarivate Plc (NYSE:CLVT; CLVT PR A) announced a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. This dividend will be paid in cash on June 1, 2022, to shareholders of record as of May 13, 2022. This decision reflects the company's commitment to returning value to its shareholders while maintaining its focus on providing trusted information and insights that accelerate innovation.
Clarivate Plc (CLVT) reported strong financial results for Q1 2022, with revenues soaring to $662.2 million, a 54.6% increase year-over-year. Organic revenues rose 4.4%, while net income improved by $106.8 million to $50.8 million. Adjusted EBITDA also saw significant growth, up 59.2% to $262.3 million. Subscription revenues increased 69%, driven by the ProQuest acquisition. However, net cash provided by operating activities decreased by 61.3% to $67.4 million, primarily due to payroll payments. The company reaffirmed its positive outlook for 2022.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
